Join
Live feed
·
PRReleasevia Quantisnow
Capricor Therapeutics Inc. logo

Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study

ByQuantisnow·Wall Street's wire, on your screen.
CAPR· Capricor Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CAPR (Capricor Therapeutics Inc.) and more on Quantisnow.